Tyrosine kinase signaling in fibrotic disorders
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Tyrosine kinases regulate a broad variety of physiological cell processes, including metabolism, growth, differentiation and apoptosis. Abnormal tyrosine kinase activity disturbs the physiological cell homeostasis and can lead to cancer, vascular disease, and fibrosis. In regard to fibrosis, different tyrosine kinases have been identified as determinants of disease progression and potential targets for anti-fibrotic therapies. This includes both receptor tyrosine kinases (e.g., PDGF receptor, VEGF receptor, EGF receptor, and JAK kinases) as well as non-receptor tyrosine kinases (e.g., c-Abl, c-Kit, and Src kinases). Given their central role in the pathogenesis of fibrosis, researchers of our field study the anti-fibrotic effects of monoclonal antibodies or small-molecule inhibitors to block the aberrant tyrosine kinase activity and treat fibrosis in preclinical models of various fibrotic diseases (e.g., idiopathic pulmonary fibrosis, renal fibrosis, liver fibrosis, and dermal fibrosis). The results of these studies were promising and prompted clinical trials with different compounds in fibrotic diseases. So far, results from studies with intedanib in idiopathic pulmonary fibrosis and imatinib in idiopathic pulmonary fibrosis and systemic sclerosis have been reported. Although none of these studies reported a positive primary outcome, promising trends in anti-fibrotic efficacy awaken our hopes for a new class of effective anti-fibrotic targeted therapies. This article is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122 · cited 2×
“variants of VEGF-A can further fine tune VEGF signaling [31].”
BackgroundRole of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Distler, J. H. W., Jüngel, A., Huber, L. C., Schulze‐Horsel, U., Zwerina, J., Gay, R. E., Michel, B. A., Hauser, T., Schett, G., Gay, S., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22314 · Cited by 383
Self-citationImatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373 · cited 1×
“The primary outcome was a combined measure of disease progression (defined as >10% decline from baseline FVC) or death, and secondary outcome measures included changes of DlCO, resting paO2, 6-minute walk test and health assessment questionnaires among others [109].”
BackgroundDistler, O., Distler, J. H. W., Scheid, A., Acker, T., Hirth, A., Rethage, J., Michel, B. A., Gay, R. E., Müller-Ladner, U., Matucci-Cerinic, M., et al. (2004) · Circulation Research · doi:10.1161/01.res.0000134644.89917.96 · Cited by 310
Self-citationIncreased PDGFRα Activation Disrupts Connective Tissue Development and Drives Systemic Fibrosis
Olson, L. E., & Soriano, P. (2009) · Developmental Cell · doi:10.1016/j.devcel.2008.12.003 · Cited by 264
Pang, M., Ma, L., Gong, R., Tolbert, E., Mao, H., Ponnusamy, M., Chin, Y. E., Yan, H., Dworkin, L. D., & Zhuang, S. (2010) · Kidney International · doi:10.1038/ki.2010.154 · Cited by 260
Hematopoietic cytokine receptor signaling
Baker, S. J., Rane, S. G., & Reddy, E. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210757 · Cited by 256
Cited by
Yang (2021) · doi:10.1038/s41598-020-79139-8 · Cited by 5,035
Burnham, E. L., Janssen, W. J., Riches, D. W. H., Moss, M., & Downey, G. P. (2014) · European Respiratory Journal · doi:10.1183/09031936.00196412 · Cited by 365
Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis
Palumbo-Zerr, K., Zerr, P., Distler, A., Fliehr, J., Mancuso, R., Huang, J., Mielenz, D., Tomcik, M., Fürnrohr, B. G., Scholtysek, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3777 · Cited by 342
Self-citationTGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 292
Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
Montero, P., Milara, J., Roger, I., & Cortijo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126211 · Cited by 254
The wound healing, chronic fibrosis, and cancer progression triad
Rybinski, B., Franco-Barraza, J., & Cukierman, E. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2013 · Cited by 253
Combination therapy: the future of management for idiopathic pulmonary fibrosis?
Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70232-2 · Cited by 150
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01209-2017 · Cited by 146
Martyanov, V., Kim, G.-H. J., Hayes, W., Du, S., Ganguly, B. J., Sy, O., Lee, S. K., Bogatkevich, G. S., Schieven, G. L., Schiopu, E., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187580 · Cited by 71
“Multiple tyrosine kinases associated with TGF-β and PDGF signaling have been implicated in skin and lung fibrosis, and are potential targets for therapy [49].”
Background
Metadata
- Authors
- Beyer, C., & Distler, J. H. W.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 1832
- Issue
- 7
- Pages
- 897-904
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W178900729
- Cited by
- 126
- References
- 13
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.